Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: In order to confirm therapeutic effects of topiramate on posttraumatic stress disorder (PTSD) observed in a prior study, a new prospective, open-label study was conducted to examine acute responses in chronic, nonhallucinatory PTSD. Methods: Thirty-three consecutive newly recruited civilian adult outpatients (mean age 46 years, 85% female) with DSM-IV-diagnosed chronic PTSD, excluding those with concurrent auditory or visual hallucinations, received topiramate either as monotherapy (n = 5) or augmentation (n = 28). The primary measure was a change in the PTSD Checklist-Civilian Version (PCL-C) score from baseline to 4 weeks, with response defined as a ≥ 30% reduction of PTSD symptoms. Results: For those taking the PCL-C at both baseline and week 4 (n = 30), total symptoms declined by 49% at week 4 (paired t-test, P < 0.001) with similar subscale reductions for reexperiencing, avoidance/numbing, and hyperarousal symptoms. The response rate at week 4 was 77%. Age, sex, bipolar comorbidity, age at onset of PTSD, duration of symptoms, severity of baseline PCL-C score, and monotherapy versus add-on medication administration did not predict reduction in PTSD symptoms. Median time to full response was 9 days and median dosage was 50 mg/day. Conclusions: Promising open-label findings in a new sample converge with findings of a previous study. The use of topiramate for treatment of chronic PTSD, at least in civilians, warrants controlled clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychometric properties of the PTSD checklist (PCL)
Blanchard, E. B., Jones-Alexander, J., Buckley, T. C., & Forneris, C. A. (1996) · Behaviour Research and Therapy · doi:10.1016/0005-7967(96)00033-2 · Cited by 3,997 · cited 1×
“The primary outcome was a change in PTSD symptoms calculated from change in PCL-C score from baseline through 4 weeks of treatment [22].”
Method
Research works printed but not linked: 30
- Breslau N: The epidemiology of posttraumatic stress disorder: what is the extent of the problem?. J Clin Psychiatry. 2001, 62 (Suppl 17): 16-22.
- van der Kolk BA: The psychobiology of posttraumatic stress disorder. J Clin Psychiatry. 1997, 58 (Suppl 9): 16-24.
- Iancu I, Rosen Y, Moshe K: Antiepileptic drugs in posttraumatic stress disorder. Clin Neuropharmacol. 2002, 25: 225-229. 10.1097/00002826-200207000-00006. · DOI
- Berlant J: Antiepileptic treatment of posttraumatic stress disorder. Primary Psychiatry. 2003, 10: 41-49.
- Davidson JR: Biological therapies for posttraumatic stress disorder: an overview. J Clin Psychiatry. 1997, 58 (Suppl 9): 29-32.
- Berlant J, van Kammen DP: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002, 63: 15-20. · DOI · Paper page
- DeLorenzo RJ, Sombati S, Coulter DA: Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia. 2000, 41 (Suppl 1): S40-44. · DOI
- Zona C, Ciotti MT, Avoli M: Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett. 1997, 231: 123-126. 10.1016/S0304-3940(97)00543-0. · doi:10.1016/s0304-3940(97)00543-0
- McLean MJ, Bukhari AA, Wamil AW: Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia. 2000, 41 (Suppl 1): S21-24. · doi:10.1111/j.1528-1157.2000.tb02166.x
- Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G: Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999, 288: 960-968.
- Wu SP, Tsai JJ, Gean PW: Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices. Br J Pharmacol. 1998, 125: 826-832. · doi:10.1038/sj.bjp.0702096
- Zhang X, Velumian AA, Jones OT, Carlen PL: Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000, 41 (Suppl 1): S52-60. · DOI · Paper page
- White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997, 28: 167-179. 10.1016/S0920-1211(97)00045-4. · DOI · Paper page
- White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000, 41 (Suppl 1): S17-20. · DOI · Paper page
- Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000, 41: S10-S16. · DOI · Paper page
- Skradski S, White HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 2000, 41: S45-S47. · DOI · Paper page
- Wauquier A, Zhou S: Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. 1996, 24: 73-77. 10.1016/0920-1211(95)00105-0. · DOI
- Amano K, Hamada K, Yagi K, Seino M: Antiepileptic effects of topiramate on amygdaloid kindling in rats. Epilepsy Res. 1998, 31: 123-128. 10.1016/S0920-1211(98)00021-7. · doi:10.1016/s0920-1211(98)00021-7
- Hamner MB: Psychotic features and combat-associated PTSD. Depress Anxiety. 1997, 5: 34-38. 10.1002/(SICI)1520-6394(1997)5:1<34::AID-DA6>3.0.CO;2-5. · DOI
- Hamner MB, Frueh BC, Ulmer HG, Arana GW: Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol Psychiatry. 1999, 45: 846-852. 10.1016/S0006-3223(98)00301-1. · DOI · Paper page
- Weathers FW, Keane TM, Davidson JR: Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety. 2001, 13: 132-156. 10.1002/da.1029. · DOI · Paper page
- Lipper S, Davidson JR, Grady TA, Edinger JD, Hammett EB, Mahorney SL, Cavenar JO: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986, 27: 849-854. · DOI · Paper page
- Fesler FA: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991, 52: 361-364.
- Clark RD, Canive JM, Calais LA, Qualls CR, Tuason VB: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress. 1999, 12: 395-401. 10.1023/A:1024797014210. · DOI · Paper page
- Petty F, Davis LL, Nugent AL, Kramer GL, Teten A, Schmitt A, Stone RC: Valproate therapy for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol. 2002, 22: 100-101. 10.1097/00004714-200202000-00021. · DOI
- Otte C, Wiedemann K, Yassouridis A, Kellner M: Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study. J Clin Psychopharmacol. 2004, 24: 106-108. 10.1097/01.jcp.0000106234.36344.a4. · DOI
- Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, Davidson JR: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999, 45: 1226-1229. 10.1016/S0006-3223(99)00011-6. · DOI · Paper page
- Hamner MB, Brodrick PS, Labbate LA: Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001, 13: 141-146. 10.1023/A:1012281424057. · DOI
- Berlant JL: Topiramate in posttraumatic stress disorder: preliminary clinical observations. J Clin Psychiatry. 2001, 62 (Suppl 17): 60-63.
- Corman CL, Leung NM, Guberman AH: Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997, 24: 240-244. · DOI · Paper page
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive olanzapine [1045] 2 Adjunctive topiramate [1026-1029] 2 (-ve)”
BackgroundPharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519
Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347
Decreased Cerebrospinal Fluid Allopregnanolone Levels in Women with Posttraumatic Stress Disorder
Rasmusson, A. M., Pinna, G., Paliwal, P., Weisman, D., Gottschalk, C., Charney, D., Krystal, J., & Guidotti, A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.026 · Cited by 276
Morgenthaler, T. I., Auerbach, S., Casey, K. R., Kristo, D., Maganti, R., Ramar, K., Zak, R., & Kartje, R. (2018) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7178 · Cited by 230
Metadata
- Authors
- Berlant, J. L.
- Venue
- BMC Psychiatry
- Published
- 2004-08-18
- Volume
- 4
- Issue
- 1
- Pages
- 24-24
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W1589966135
- Cited by
- 88
- References
- 1
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. https://app.cochat.ai/papers/10.1186/1471-244x-4-24
- The paper
- Berlant, J. L. (2004). Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. https://doi.org/10.1186/1471-244x-4-24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.